7.7.4. integration agents. 7.7.4.1. antibody drug conjugates enfortumab vedotin monotherapy first antibody drug conjugate report encouraging data patients previously treated platinum-based chemotherapy checkpoint inhibition ev. phase-ii single-arm study ev-201 125 patients showed confirmed objective response rate 44%, including 12% complete responses . data led accelerated fda ema approval ev locally-advanced metastatic uc patients previously received pd-1 pd-l1 inhibitor platinum-containing chemotherapy, well cisplatin-ineligible patients received one prior lines therapy . another cohort ev-201 trial demonstrated similar promising results 91 patients cisplatin-ineligible received prior io . phase iii rct (n = 608) comparing ev single-agent chemotherapy prior platinum chemotherapy checkpoint inhibitor immunotherapy demonstrated significant survival benefit almost 4 months (12.88 months vs. 8.97 months; hr 0.7, 95% ci: 0.56–0.89) . common treatment-related aes included alopecia (45%), peripheral neuropathy (34%), fatigue (31%, 7.4% ≥ grade 3), decreased appetite (31%), diarrhoea (24%), nausea (23%) skin rash (16%, 7.4% ≥ grade 3). 7.7.4.2. antibody drug conjugate sacituzumab govetican another new also promising antibody drug conjugate sacituzumab govitecan, consisting humanised monoclonal antibody targeting trophoblast cell surface antigen 2 (trop-2) conjugated sn-38, active metabolite irinotecan. sacituzumab govitecan tested 113 platinum immunotherapy pre-treated metastatic uc (muc) patients achieved orr 27% total 77% decrease measurable disease, median pfs 5.4 months median os 10.9 months . side effects consisted haematological toxicities (neutropenia 34% ≥ grade 3; febrile neutropenia 10% ≥ grade 3), fatigue (52%), alopecia (47%), nausea (60%), diarrhea (65%, 10% ≥ grade 3) decreased appetite (36%) . sacituzumab govitecan received accelerated fda approval metastatic uc prior platinum io pre-treatment. several trials using sacituzumab govitecan monotherapy combination ongoing. 7.7.4.3. fgfr inhibition genomic profiling uc revealed common potentially actionable genomic alterations including alterations fgfr . erdafitinib pan-fgfr tyrosine kinase inhibitor first fda-approved targeted therapy muc susceptible fgfr2/3 alterations following platinum-containing chemotherapy. phase ii trial erdafitinib included 99 patients whose tumour harboured fgfr3 mutation fgfr2/3 fusion disease progression following chemotherapy . confirmed orr 40% additional 39% patients stable disease. total 22 patients previously received immunotherapy one patient achieving response, yet response rate erdafitinib subgroup 59%. median follow-up 24 months, median pfs 5.5 months (95% ci: 4.0–6.0) median os 11.3 months (95% ci: 9.7–15.2) . treatment-related aes ≥ grade 3 occurred 46% patients. common aes ≥ grade 3 hyponatraemia (11%), stomatitis (10%), asthenia (7%) 13 patients discontinued erdafitinib due aes, including retinal pigment epithelial detachment, hand-foot syndrome, dry mouth, skin/nail events. long-term follow up, efficacy safety profile remained similar new safety signals longer follow-up . recent thor cohort 1 trial, phase 3 trial erdafitinib compared chemotherapy (docetaxel vinflunine) patients metastatic uc susceptible fgfr3/2 alterations progression one two previous treatments included anti–pd-1 anti–pd-l1 demonstrated improvement os erdafitinib compared chemotherapy (12.1 months vs. 7.8 months; hr 0.64 (0.47 0.88); p=0.005). median pfs also longer erdafitinib chemotherapy (5.6 vs. 2.7 months; (hr 0.58 (0.44 -0.78) . treatment-related toxicity grade ≥ 3 similar two groups. common treatment-related adverse events grade 3 higher palmar–plantar erythrodysesthesia syndrome (9.6%), stomatitis (8.1%), onycholysis (5.9%), hyperphosphatemia (5.2%) erdafitinib group. data cohort 2 351 patients, anti-pd-(l1) naïve progressing one prior treatment line compared erdafitinib pembrolizumab. difference primary endpoint os detected (10.9 versus 11.1 months, hr 1.18 (0.92-1.51) . overall response rate 40.0% 21.6% median duration response 4.3 14.4 months erdafitinib pembrolizumab, respectively. 64.7% 50.9% patients erdafitinib pembrolizumab arms ≥ 1 grade 3-4 adverse events. addition erdafitinib, several fgfr inhibitors evaluated including infigratinib demonstrated promising activity . phase 2/3 trial pan-fgfr inhibitor, rogaratinib versus chemotherapy patients locally advanced metastatic uc fgfr1-3 mrna overexpression demonstrated similar outcomes compared chemotherapy . increased identification fgfr3 mutations/fusion led several ongoing trials different agents combinations different disease settings.